BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36669725)

  • 1. Synergistic efficacy of telomerase-specific oncolytic adenoviral therapy and histone deacetylase inhibition in human hepatocellular carcinoma.
    Lin ZZ; Hu MC; Hsu C; Wu YM; Lu YS; Ho JA; Yeh SH; Chen PJ; Cheng AL
    Cancer Lett; 2023 Mar; 556():216063. PubMed ID: 36669725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telomerase-specific oncolytic adenoviral therapy for orthotopic hepatocellular carcinoma in HBx transgenic mice.
    Lin WH; Yeh SH; Yang WJ; Yeh KH; Fujiwara T; Nii A; Chang SS; Chen PJ
    Int J Cancer; 2013 Mar; 132(6):1451-62. PubMed ID: 22886913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient virotherapy for osteosarcoma by telomerase-specific oncolytic adenovirus.
    Li G; Kawashima H; Ogose A; Ariizumi T; Xu Y; Hotta T; Urata Y; Fujiwara T; Endo N
    J Cancer Res Clin Oncol; 2011 Jun; 137(6):1037-51. PubMed ID: 21193997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitor AR42 regulates telomerase activity in human glioma cells via an Akt-dependent mechanism.
    Yang YL; Huang PH; Chiu HC; Kulp SK; Chen CS; Kuo CJ; Chen HD; Chen CS
    Biochem Biophys Res Commun; 2013 May; 435(1):107-12. PubMed ID: 23624506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma.
    Kondo N; Tsukuda M; Kimura M; Fujita K; Sakakibara A; Takahashi H; Ishiguro Y; Toth G; Matsuda H
    Oncol Rep; 2010 Feb; 23(2):355-63. PubMed ID: 20043095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model.
    El-Shemi AG; Ashshi AM; Na Y; Li Y; Basalamah M; Al-Allaf FA; Oh E; Jung BK; Yun CO
    J Exp Clin Cancer Res; 2016 May; 35():74. PubMed ID: 27154307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1.
    Wirth T; Kühnel F; Fleischmann-Mundt B; Woller N; Djojosubroto M; Rudolph KL; Manns M; Zender L; Kubicka S
    Cancer Res; 2005 Aug; 65(16):7393-402. PubMed ID: 16103092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses.
    Kishimoto H; Urata Y; Tanaka N; Fujiwara T; Hoffman RM
    Mol Cancer Ther; 2009 Nov; 8(11):3001-8. PubMed ID: 19887549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin.
    Ma B; Wang Y; Zhou X; Huang P; Zhang R; Liu T; Cui C; Liu X; Wang Y
    J Cancer Res Clin Oncol; 2015 Mar; 141(3):419-29. PubMed ID: 25240826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Examination of the optimal condition on the in vitro sensitivity to telomelysin in head and neck cancer cell lines.
    Sakakibara A; Tsukuda M; Kondo N; Ishiguro Y; Kimura M; Fujita K; Takahashi H; Matsuda H
    Auris Nasus Larynx; 2011 Oct; 38(5):589-99. PubMed ID: 21362583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
    Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
    Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced antitumor efficacy of a novel fiber chimeric oncolytic adenovirus expressing p53 on hepatocellular carcinoma.
    Chen W; Wu Y; Liu W; Wang G; Wang X; Yang Y; Chen W; Tai Y; Lu M; Qian Q; Zhang Q; Chen G
    Cancer Lett; 2011 Aug; 307(1):93-103. PubMed ID: 21504839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The oncolytic adenovirus targeting to TERT and RB pathway induced specific and potent anti-tumor efficacy in vitro and in vivo for hepatocellular carcinoma.
    Zhang W; Cai R; Luo J; Wang Y; Cui Q; Wei X; Zhang H; Qian C
    Cancer Biol Ther; 2007 Nov; 6(11):1726-32. PubMed ID: 18281783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA.
    Gao Y; Zhu Y; Huang X; Ai K; Zheng Q; Yuan Z
    Int J Oncol; 2015 Aug; 47(2):668-78. PubMed ID: 26081241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
    Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
    Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.
    Watanabe Y; Hashimoto Y; Kagawa S; Kawamura H; Nagai K; Tanaka N; Urata Y; Fujiwara T
    Cancer Gene Ther; 2012 Nov; 19(11):767-72. PubMed ID: 22956040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telomelysin shows potent antitumor activity through apoptotic and non-apoptotic cell death in soft tissue sarcoma cells.
    Li GD; Kawashima H; Ogose A; Ariizumi T; Hotta T; Kuwano R; Urata Y; Fujiwara T; Endo N
    Cancer Sci; 2013 Sep; 104(9):1178-88. PubMed ID: 23718223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An oncolytic adenovirus regulated by a radiation-inducible promoter selectively mediates hSulf-1 gene expression and mutually reinforces antitumor activity of I131-metuximab in hepatocellular carcinoma.
    Zhang Y; Fang L; Zhang Q; Zheng Q; Tong J; Fu X; Jiang X; Su C; Zheng J
    Mol Oncol; 2013 Jun; 7(3):346-58. PubMed ID: 23182495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors.
    Nemunaitis J; Tong AW; Nemunaitis M; Senzer N; Phadke AP; Bedell C; Adams N; Zhang YA; Maples PB; Chen S; Pappen B; Burke J; Ichimaru D; Urata Y; Fujiwara T
    Mol Ther; 2010 Feb; 18(2):429-34. PubMed ID: 19935775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of an hTERT promoter-regulated tumor-selective oncolytic adenovirus in human hepatocellular carcinoma.
    Su CQ; Wang XH; Chen J; Liu YJ; Wang WG; Li LF; Wu MC; Qian QJ
    World J Gastroenterol; 2006 Dec; 12(47):7613-20. PubMed ID: 17171789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.